Biogen Makes Gene Therapy Splash as Street Wonders What's Next
(Bloomberg) -- Biogen Inc.'s plan to buy gene therapy developer Nightstar Therapeutics Plc brings a much needed deal to help diversify away from its high-risk Alzheimer's drugs, but the pact left some on Wall Street craving more.
The $877 million deal is in-line with management's promise to diversify its drug portfolio with later-stage assets and take some of the risk off next year's closely watched catalyst -- late-stage data for the Alzheimer's treatment aducanumab. Analysts including Jefferies's Michael Yee said Biogen still needs to do more to move the needle.
“Investors have wanted Biogen to do a lot more to de-risk Alzheimer's and the big data in 2020,” Yee wrote in a note to clients. “Biogen bulls want the company to buy late-stage neuro assets such as in DMD, depression, or in other much bigger markets that will move the needle sooner on a $65B market cap company.”
Shares of the Cambridge, Massachusetts-based drugmaker fell 0.2 percent at 10:45 a.m. in New York. Nightstar jumped 66 percent to $25.18, just shy of the $25.50-a-share offer.
The acquisition comes just a week after Roche Holding AG made a $4.8 billion bid for Spark Therapeutics Inc. Nightstar's pipeline includes a pair of late-stage treatment candidates for rare inherited retinal diseases. Biogen's portfolio is mostly focused in neuroscience.
“While today's deal doesn't quite address Biogen's critical need for transformative business development, we are positive on the acquisition,” Barclays analyst Geoff Meacham wrote. He is keeping a neutral outlook on the company until there's more clarity on the pipeline.
To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net
To contact the editor responsible for this story: Catherine Larkin at clarkin4@bloomberg.net
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
